SciSparc Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
SPRC
- Investments
-
6
- Share Price
-
$0.22
- (As of Monday Closing)
SciSparc General Information
Description
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact Information
Website
www.scisparc.comCorporate Office
- 20 Raoul Wallenberg Street
- Tower A, 2nd Floor
- Tel Aviv 6971916
- Israel
Corporate Office
- 20 Raoul Wallenberg Street
- Tower A, 2nd Floor
- Tel Aviv 6971916
- Israel
SciSparc Timeline
SciSparc Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.22 | $0.22 | $0.21 - $14.22 | $2.27M | 10.4M | 3.78M | -$12.55 |
SciSparc Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 3,157 | 3,157 | (10,236) | 359,981 |
| Revenue | 2,879 | 2,879 | 1,347 | 0 |
| EBITDA | (5,314) | (5,314) | (2,355) | (5,744) |
| Net Income | (5,122) | (5,122) | (2,592) | (5,789) |
| Total Assets | 11,182 | 11,182 | 10,605 | 9,916 |
| Total Debt | 76 | 76 | 27 | 63 |
SciSparc Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SciSparc Comparisons
Industry
Financing
Details
SciSparc Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Acerus Pharmaceuticals | Corporation | Mississauga, Canada | ||||
| Antares Pharma | Formerly VC-backed | Ewing, NJ | ||||
| Hua Medicine | Formerly VC-backed | Pudong, China | ||||
| Lipocine | Corporation | Salt Lake City, UT | ||||
| Medexus Pharmaceuticals | Corporation | Toronto, Canada |
SciSparc Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
SciSparc Patents
SciSparc Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3172130-A1 | Methods for maintaining microvascular integrity using cannabinoid-based compositions | Pending | 03-Aug-2020 | ||
| AU-2021322987-A1 | Methods for maintaining microvascular integrity | Pending | 03-Aug-2020 | ||
| EP-4188364-A1 | Methods for maintaining microvascular integrity | Pending | 03-Aug-2020 | ||
| US-20230302025-A1 | Methods for maintaining microvascular integrity | Pending | 03-Aug-2020 | ||
| EP-4188364-A4 | Methods for maintaining microvascular integrity | Pending | 03-Aug-2020 | A61K31/658 |
SciSparc Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Oz Adler | Chief Executive and Financial Officer | |
| Itschak Shrem | Board Member & President | |
| Adi Shani Ph.D | Chief Technology Officer | |
| Yaki Baranes | Vice President of Strategy & Business Development |
SciSparc Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | External Director | ||
| SciSparc | Board Member & President | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member |
SciSparc Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SciSparc Investments & Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MitoCareX Bio | 27-Nov-2023 | Biotechnology | |||
| MitoCareX Bio | 17-Feb-2023 | Biotechnology | |||
| Wellution | 30-Sep-2022 | Food Products | |||
| MitoCareX Bio | 01-Jan-2022 | Biotechnology | |||
| Dekel Pharmaceuticals | 21-Oct-2014 | Merger/Acquisition | Drug Discovery |
SciSparc Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| MitoCareX Bio | Biotechnology | Tel-Aviv-Jaffa, Israel | 2022 |
| Lara Pharm | Drug Discovery | Tel Aviv, Israel | |
| Wellution | Food Products | Boulder, CO |
SciSparc FAQs
-
When was SciSparc founded?
SciSparc was founded in 2004.
-
Who is the CEO of SciSparc?
Oz Adler is the CEO of SciSparc.
-
Where is SciSparc headquartered?
SciSparc is headquartered in Tel Aviv, Israel.
-
What is the size of SciSparc?
SciSparc has 3 total employees.
-
What industry is SciSparc in?
SciSparc’s primary industry is Drug Discovery.
-
Is SciSparc a private or public company?
SciSparc is a Public company.
-
What is SciSparc’s stock symbol?
The ticker symbol for SciSparc is SPRC.
-
What is the current stock price of SciSparc?
As of 07-Oct-2024 the stock price of SciSparc is $0.22.
-
What is the current market cap of SciSparc?
The current market capitalization of SciSparc is $2.27M.
-
What is SciSparc’s current revenue?
The trailing twelve month revenue for SciSparc is $2.88M.
-
Who are SciSparc’s competitors?
Acerus Pharmaceuticals, Antares Pharma, Hua Medicine, Lipocine, and Medexus Pharmaceuticals are some of the 8 competitors of SciSparc.
-
What is SciSparc’s annual earnings per share (EPS)?
SciSparc’s EPS for 12 months was -$12.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
